JP2019520058A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520058A5 JP2019520058A5 JP2018561062A JP2018561062A JP2019520058A5 JP 2019520058 A5 JP2019520058 A5 JP 2019520058A5 JP 2018561062 A JP2018561062 A JP 2018561062A JP 2018561062 A JP2018561062 A JP 2018561062A JP 2019520058 A5 JP2019520058 A5 JP 2019520058A5
- Authority
- JP
- Japan
- Prior art keywords
- flavivirus
- analog
- protein
- analogue
- den
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608896.5 | 2016-05-20 | ||
| GB1608896.5A GB2550418A (en) | 2016-05-20 | 2016-05-20 | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| PCT/US2017/033882 WO2017201543A1 (en) | 2016-05-20 | 2017-05-22 | Variant flavivirus envelope sequences and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520058A JP2019520058A (ja) | 2019-07-18 |
| JP2019520058A5 true JP2019520058A5 (https=) | 2020-07-02 |
| JP7121396B2 JP7121396B2 (ja) | 2022-08-18 |
Family
ID=56369688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018561062A Active JP7121396B2 (ja) | 2016-05-20 | 2017-05-22 | バリアントフラビウイルスエンベロープ配列およびその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11028133B2 (https=) |
| EP (2) | EP3458471B1 (https=) |
| JP (1) | JP7121396B2 (https=) |
| KR (1) | KR20190008896A (https=) |
| CN (1) | CN109415414A (https=) |
| AU (1) | AU2017268479B2 (https=) |
| BR (1) | BR112018073681A2 (https=) |
| CA (1) | CA3025076A1 (https=) |
| DK (1) | DK3458471T3 (https=) |
| GB (2) | GB2550418A (https=) |
| HU (1) | HUE049543T2 (https=) |
| IL (1) | IL263054A (https=) |
| MX (1) | MX2018014198A (https=) |
| PE (1) | PE20190130A1 (https=) |
| PH (1) | PH12018502441A1 (https=) |
| RU (1) | RU2018142835A (https=) |
| SG (1) | SG11201810157QA (https=) |
| WO (2) | WO2017201543A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
| EP3474891B1 (en) * | 2016-06-23 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Vaccine compositions comprising an attenuated mutant zika virus |
| EP3621645A4 (en) | 2017-05-10 | 2021-01-27 | University of Massachusetts | BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B |
| TWI658848B (zh) * | 2018-02-13 | 2019-05-11 | National Tsing Hua University | 茲卡病毒疫苗組合物及其應用 |
| CN109627294B (zh) * | 2018-12-29 | 2020-10-09 | 四川大学 | 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用 |
| WO2020198865A1 (en) * | 2019-04-03 | 2020-10-08 | The University Of British Columbia | Oligopeptides for quantitative viral proteomic analysis methods and uses |
| KR20220093197A (ko) * | 2019-11-07 | 2022-07-05 | 인스티튜트 오브 마이크로바이올로지, 차이니즈 아카데미 오브 사이언스즈 | 지카/뎅기열 백신 및 이의 응용 |
| WO2022074111A1 (en) * | 2020-10-07 | 2022-04-14 | Sanofi Pasteur | Improved diagnostic tests |
| CN117157524A (zh) * | 2020-10-07 | 2023-12-01 | 赛诺菲巴斯德有限公司 | 改良的诊断测试 |
| GB202019843D0 (en) | 2020-12-16 | 2021-01-27 | Coronex Ltd | Lateral flow tests |
| EP4602057A1 (en) * | 2022-10-11 | 2025-08-20 | University of Maryland, Baltimore | Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057534C (zh) | 1993-08-17 | 2000-10-18 | 柯瑞英-艾格公司 | 促红细胞生成素类似物 |
| CA2616026A1 (en) * | 2005-07-22 | 2007-02-08 | Research Development Foundation | Attenuated strains of flaviviruses , and uses thereof |
| US7943148B1 (en) * | 2007-04-04 | 2011-05-17 | The United States Of America As Represented By The Secretary Of The Army | Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines |
| US9821050B2 (en) * | 2012-04-02 | 2017-11-21 | The University Of North Carolina At Chapel Hill | Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions |
| GB201413086D0 (en) * | 2014-07-23 | 2014-09-03 | Imp Innovations Ltd And Inst Pasteur | Methods |
| GB2550418A (en) * | 2016-05-20 | 2017-11-22 | Laing Peter | An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies |
-
2016
- 2016-05-20 GB GB1608896.5A patent/GB2550418A/en not_active Withdrawn
-
2017
- 2017-05-22 US US16/303,588 patent/US11028133B2/en not_active Expired - Fee Related
- 2017-05-22 CA CA3025076A patent/CA3025076A1/en active Pending
- 2017-05-22 JP JP2018561062A patent/JP7121396B2/ja active Active
- 2017-05-22 PE PE2018003079A patent/PE20190130A1/es unknown
- 2017-05-22 SG SG11201810157QA patent/SG11201810157QA/en unknown
- 2017-05-22 EP EP17726515.4A patent/EP3458471B1/en not_active Not-in-force
- 2017-05-22 AU AU2017268479A patent/AU2017268479B2/en not_active Ceased
- 2017-05-22 DK DK17726515.4T patent/DK3458471T3/da active
- 2017-05-22 KR KR1020187036317A patent/KR20190008896A/ko not_active Abandoned
- 2017-05-22 WO PCT/US2017/033882 patent/WO2017201543A1/en not_active Ceased
- 2017-05-22 BR BR112018073681-3A patent/BR112018073681A2/pt not_active IP Right Cessation
- 2017-05-22 CN CN201780040802.7A patent/CN109415414A/zh active Pending
- 2017-05-22 HU HUE17726515A patent/HUE049543T2/hu unknown
- 2017-05-22 RU RU2018142835A patent/RU2018142835A/ru not_active Application Discontinuation
- 2017-05-22 MX MX2018014198A patent/MX2018014198A/es unknown
- 2017-11-22 GB GBGB1719423.4A patent/GB201719423D0/en not_active Ceased
-
2018
- 2018-05-22 EP EP18725547.6A patent/EP3630796A1/en not_active Withdrawn
- 2018-05-22 US US16/615,788 patent/US11401307B2/en active Active
- 2018-05-22 WO PCT/EP2018/063422 patent/WO2018215495A1/en not_active Ceased
- 2018-11-15 IL IL263054A patent/IL263054A/en unknown
- 2018-11-20 PH PH12018502441A patent/PH12018502441A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520058A5 (https=) | ||
| RU2018142835A (ru) | Вариантные последовательности оболочки флавивируса и пути их применения | |
| US20250171501A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| JP6018575B2 (ja) | デングウイルス組換えサブユニットスワクチン | |
| KR101500017B1 (ko) | 재조합 ｈｃｖ ｅ2 당단백질 | |
| AU2007246076B2 (en) | Methods for the treatment of flavivirus infection, molecules and uses thereof | |
| US10098943B2 (en) | Flavivirus virus like particle | |
| US20110129498A1 (en) | Vaccine for the prevention and therapy of hcv infections | |
| WO2002086101A2 (en) | Core-glycosylated hcv envelope proteins | |
| AU2002257392A1 (en) | Core-glycosylated hcv envelope proteins | |
| JP2001511459A (ja) | フラビウイルス感染に対抗する組換え二量体エンベロープワクチン | |
| KR20230009445A (ko) | 안정화된 코로나바이러스 스파이크 단백질 융합 단백질 | |
| JP2020509770A5 (https=) | ||
| CN111132692A (zh) | 包含寨卡病毒抗原的病毒样颗粒 | |
| KR20140036127A (ko) | 조성물 및 방법 | |
| Ganguly et al. | Enhanced prokaryotic expression of dengue virus envelope protein | |
| AU718740B2 (en) | Polyvalent anti-dengue vaccine | |
| CN105330730A (zh) | 一种丙型肝炎病毒重组蛋白的制备及其应用 | |
| CN107074968B (zh) | 疫苗 | |
| CN113736825B (zh) | 一种表达猪非典型瘟病毒融合蛋白的重组果蝇细胞系及其制备方法和应用 | |
| US20250002566A1 (en) | Polynucleotide, expression cassette, vector, host cell, polypeptide, pharmaceutical composition, use of a polypeptide, method for producing a polypeptide, and method for preventing or treating infections caused by flaviviruses | |
| CN114634579A (zh) | 一种抗新冠病毒基因工程疫苗 | |
| Aghasadeghi et al. | Evaluation of a native preparation of HCV core protein (2-122) for potential applications in immunization, diagnosis and mAb production | |
| WO2025101636A1 (en) | Flavivirus vaccine composition | |
| WO2017031280A1 (en) | Fusion proteins that include dengue antigens and methods of use |